Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase
III ACTIVE Study (CTONG1706) | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Methods Treatment-naive patients with stage IIIB or IV nonsquamous NSCLC, an Eastern
Cooperative Oncology Group performance status of 0 or 1, and EGFR exon 19 deletion or …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …